...
首页> 外文期刊>Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society >Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation.
【24h】

Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation.

机译:并发自体免疫性肝炎和肝移植后原发性胆汁性肝硬化的复发。

获取原文
获取原文并翻译 | 示例

摘要

Primary biliary cirrhosis (PBC) is well known to recur after liver transplantation (LT). The recurrence is usually subclinical and evident only on histological examination. Recently, a new entity of de novo autoimmune hepatitis (AIH) has emerged that occurs after LT in patients who underwent transplantation for diseases other than AIH. This new condition occurs more often in children; however, there was a recent report of the first 2 cases in adults who originally underwent LT for PBC. We report the first case of concurrent de novo AIH and recurrence of PBC documented on the liver biopsy of an adult patient who underwent LT for end-stage PBC. Unlike the earlier report of 2 adults, our patient manifested an antinuclear antibody titer of more than 1/800 from a previously negative titer pre-LT, as well as fulfilled the International AIH Group criteria for a definite diagnosis of AIH. PBC recurrence was evidenced by typical florid duct lesion, antimitochondrial antibody titer increasing from 1/40 to greater than 1/800, and an elevated serum immunoglobulin M level. After the addition of azathioprine to baseline immunosuppression of tacrolimus and prednisolone, the patient responded rapidly, with complete normalization of liver test results.
机译:众所周知,原发性胆汁性肝硬化(PBC)在肝移植(LT)后会复发。复发通常是亚临床的,仅在组织学检查中才可见。最近,出现了一种新的从头自身免疫性肝炎(AIH)实体,该实体发生在LT术后因AIH以外的疾病接受移植的患者中。这种新病多见于儿童。然而,最近有报道说,最初对PBC进行LT的成年人中有前2例。我们报道了第一例并发从头AIH和PBC复发的成年患者肝活检记录的PBC复发,该患者接受了LT末期PBC。与2位成年人的早期报道不同,我们的患者从先前的LT前阴性抗体滴度中获得了超过1/800的抗核抗体滴度,并且满足了AIH明确诊断AIH组的标准。 PBC复发通过典型的小管导管病变,抗线粒体抗体滴度从1/40增加到大于1/800以及血清免疫球蛋白M水平升高来证明。在他克莫司和泼尼松龙的基线免疫抑制中加入硫唑嘌呤后,患者反应迅速,肝脏测试结果完全正常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号